Patents by Inventor Jesper Lau

Jesper Lau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 7851636
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: December 14, 2010
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaram Santhosh
  • Novel GLP-1 Derivatives
    Publication number: 20100305032
    Abstract: Novel polypeptide derivatives having protracted profile of action.
    Type: Application
    Filed: May 5, 2010
    Publication date: December 2, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
  • TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE
    Publication number: 20100292133
    Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.
    Type: Application
    Filed: September 5, 2008
    Publication date: November 18, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, János Tibor Kodra, Kjeld Madsen, Patrick William Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thøgersen, Igrid Pettersson
  • PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE
    Publication number: 20100261637
    Abstract: The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Application
    Filed: September 5, 2008
    Publication date: October 14, 2010
    Applicant: Novo nordisk A/S
    Inventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Søren Østergaard, Steffen Reedtz-Runge, Henning Thøgersen
  • IMPROVED DERIVATIVES OF AMYLIN
    Publication number: 20100222269
    Abstract: The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such.
    Type: Application
    Filed: September 11, 2008
    Publication date: September 2, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Lauge Schäffer, Thomas Kruse, Jesper Lau
  • Heteroaryl-Ureas and Their Use as Glucokinase Activators
    Publication number: 20100204288
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 12, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
  • Peptides for Treatment of Obesity
    Publication number: 20100173835
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: November 25, 2009
    Publication date: July 8, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
  • Urea Glucokinase Activators
    Publication number: 20100041711
    Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
    Type: Application
    Filed: January 8, 2008
    Publication date: February 18, 2010
    Applicant: Novo Nordisk A/s
    Inventors: Anthony Murray, Jesper Lau, Per Vedsø, Lisa Brown Christiansen
  • Peptides for Use in the Treatment of Obesity
    Publication number: 20100016238
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: January 17, 2008
    Publication date: January 21, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Ulrich Sensfuss, Jesper Lau
  • TREATING DIABETES USING INHIBITORS OF IL-1
    Publication number: 20100015146
    Abstract: The present invention describes a method of treating diabetes or metabolic syndrome with a compound that inhibits (a) IL-1, (b) the synthesis of IL-1, or (c) the release of IL-1.
    Type: Application
    Filed: October 11, 2006
    Publication date: January 21, 2010
    Applicant: Novo Nordisk A/S
    Inventor: Jesper Lau
  • Urea Glucokinase Activators
    Publication number: 20100009989
    Abstract: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such.
    Type: Application
    Filed: January 8, 2008
    Publication date: January 14, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedsø
  • Acylated Exendin-4 Compounds
    Publication number: 20090318353
    Abstract: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.
    Type: Application
    Filed: August 24, 2007
    Publication date: December 24, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Thomas Kruse Hansen, Leif Christensen, Kjeld Madsen, Lauge Schäffer, Jane Spetzler
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 7598391
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: October 6, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
  • Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides
    Publication number: 20090240028
    Abstract: The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein.
    Type: Application
    Filed: November 24, 2008
    Publication date: September 24, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Carsten Behrens, Florencio Zaragoza Dorwald, Mikael Kofod-Hansen, Jesper Lau, Janos Tibor Kodra, Thomas Kruse Hansen, Paw Bloch
  • Dicycloalkyl urea glucokinase activators
    Patent number: 7582769
    Abstract: Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: September 1, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Heteroaryl-Ureas and Their Use as Glucokinase Activators
    Publication number: 20090216013
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: August 8, 2008
    Publication date: August 27, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedso, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswara Santhosh
  • BENZAMIDE GLUCOKINASE ACTIVATORS
    Publication number: 20090176991
    Abstract: The present invention relates to N-heteroaryl-benzamides of the formula (I), pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful as glucokinase activators.
    Type: Application
    Filed: April 27, 2007
    Publication date: July 9, 2009
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedso
  • Acylated GLP-1 Compounds
    Publication number: 20090156478
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 20, 2006
    Publication date: June 18, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dorwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases
    Publication number: 20090149512
    Abstract: Ghrelin antagonists can be used for the treatment of certain CNS disorders. For example, certain oxadiazoles, preferably such being ghrelin antagonists, can be used to treat obesity, e.g., drug-induced obesity.
    Type: Application
    Filed: May 13, 2005
    Publication date: June 11, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Kirsten Raun, Lotte Bjerre Knudsen, Elene J.Hother Carlsen, Bernd Peschke, Jesper Lau, Karin Rimwall
  • Glucagon Antagonists/Inverse Agonists
    Publication number: 20090143592
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: December 3, 2007
    Publication date: June 4, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi